The therapeutic potential of targeting LYAR in gastric cancer

To investigate the expression of Ly1 antibody-reactive clone (LYAR) in gastric cancer (GC) tissues and predict potential drugs targeting its sensitivity.
We assessed the standardized mean difference (SMD) of LYAR mRNA expression across 20 GC datasets (1,804 GC samples, 858 normal tissues) using multi-center high-throughput data, in-house immunohistochemistry, and CCLE cell expression data. Clinical and pathological relevance of LYAR was evaluated using metrics such as receiver operating characteristic curve, sensitivity, specificity, and likelihood ratios. Additionally, upstream transcriptional regulation and enrichment analyses were performed, and drug sensitivity analysis identified potential drugs for high LYAR expression.
LYAR expression was significantly upregulated in GC (SMD: 1.20, 95% CI: 0.89–1.51). The area under the curve was 0.89 (95% CI: 0.86–0.92), with sensitivity 0.74 (95% CI: 0.66–0.81) and specificity 0.89 (95% CI: 0.82–0.94). MYC potentially enhances LYAR expression, promoting GC progression. High LYAR expression indicates sensitivity to AZD compounds.
LYAR overexpression promotes GC progression and tumorigenesis, suggesting its potential as a therapeutic target.

LYAR expression is significantly upregulated in gastric cancer (GC) tissues compared to normal gastric tissues.
LYAR mRNA expression levels were assessed across 20 GC datasets, including 1,804 GC samples and 858 normal tissues, using multi-center high-throughput data.
Clinical and pathological relevance of LYAR expression was evaluated using receiver operating characteristic curves, sensitivity, specificity, and likelihood ratios.
MYC is identified as a potential regulator that enhances LYAR expression and promotes GC progression.
High LYAR expression is associated with sensitivity to AZD compounds, suggesting a potential therapeutic approach.
LYAR overexpression promotes GC progression and tumorigenesis, highlighting its potential as a novel therapeutic target for GC.

LYAR expression is significantly upregulated in gastric cancer (GC) tissues compared to normal gastric tissues.
LYAR mRNA expression levels were assessed across 20 GC datasets, including 1,804 GC samples and 858 normal tissues, using multi-center high-throughput data.
Clinical and pathological relevance of LYAR expression was evaluated using receiver operating characteristic curves, sensitivity, specificity, and likelihood ratios.
MYC is identified as a potential regulator that enhances LYAR expression and promotes GC progression.
High LYAR expression is associated with sensitivity to AZD compounds, suggesting a potential therapeutic approach.
LYAR overexpression promotes GC progression and tumorigenesis, highlighting its potential as a novel therapeutic target for GC.
This study investigates the role of a protein called Ly1 antibody-reactive clone (LYAR) in gastric cancer (GC). The research examines over 2,600 samples and shows that LYAR is found at higher levels in GC tissues compared to normal tissues. Higher LYAR levels are linked to the progression of GC and could help doctors identify potential treatments. The study also finds that drugs targeting LYAR may be effective in treating GC. Additionally, understanding how LYAR works in cells could lead to new ways to slow down or stop cancer growth.